Cooperative Agreement 2448820
- The National Science Foundation (NSF) awarded a $271,443 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to Mammae Biosciences, Inc., a minority-owned, for-profit, woman-owned business and manufacturer, to develop an enzymatic method to produce compounds found in human milk at commercial scale. The goal is to assess an affordable enzymatic process for generating marketable natural compounds usually found in human milk, such as N-acetylglucosamine...
- The National Science Foundation (NSF) awarded a $2,375,361 Cooperative Agreement to Koliber Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop computational tools that leverage artificial intelligence and machine learning to design improved protein "transporter" molecules. These transporter proteins control the movement of valuable chemicals in and out of cells, which is a critical limitation in microbial...
- This Cooperative Agreement award, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, supports the development of a novel platform for protein engineering and production using a hybrid in-vivo, in-vitro, and in-silico approach. The $2,808,001 project, executed by Caravel Bio, Inc., aims to overcome the high costs and scalability challenges of cell-free biosynthesis through the integration of four advanced technologies:...
- The National Science Foundation (NSF) awarded a $2,686,207 Cooperative Agreement titled "IDEAS LAB: USPRD: DE NOVO DESIGN AND EVOLUTION OF ENZYMES FOR BIOMASS UPCYCLING TO SURFACTANTS AND FUELS" under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to transform plant materials into high-value products like fuels, oils, and surfactants using artificial intelligence and machine learning to enhance the activity of key enzymes for biomass...
- The National Science Foundation (NSF) awarded a $1,250,000 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Cascade Biocatalysts Inc. This funding supports the development of a proprietary polymerization technique to create polymer brushes that stabilize enzymes for use in advanced chemical manufacturing processes. The key objectives are to enable a lower-cost and scalable solution for biomanufacturing by increasing the stability and...
- The National Science Foundation (NSF) awarded a $2,526,095 Cooperative Agreement to Arzeda Corp, a biotechnology company based in Seattle, Washington, under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). The project aims to transform the electrochemical conversion of carbon dioxide (CO2) to methanol by developing a highly efficient, cell-free enzymatic cascade system. The research will integrate AI-driven enzyme design, synthetic chemistry, and advanced...
- This $2,996,108 Cooperative Agreement awarded by the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop more efficient cell-free biomanufacturing processes. The project is creating membraneless compartmentalization techniques using custom-designed enzymes and innovative materials. This approach enables the simultaneous execution of multiple redox reactions required to produce valuable chiral chemicals, overcoming the...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) award provides $274,727 to Weka Biosciences LLC, a woman-owned small business, to develop a novel microbial process for creating a synthetic sugar polymer for use in chiral chromatography. The goal is to produce a more reliable and efficient polymer material to enhance the precision of drug manufacturing and contribute to safer, more effective medications. The 12-month project will focus on...
- This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program provides $2,233,515 to support a project by Arzeda Corp to transform the production of acrylates through the use of AI-designed enzymes and non-natural cofactors. The project aims to develop a scalable, cost-effective, and cell-free biocatalytic process for producing methylene butyrolactone (MBL), a bio-based acrylate monomer. This will involve engineering...
- This Cooperative Agreement from the National Science Foundation will support Sasya Inc.'s research and development of sustainable production methods for high-performance dietary supplements through July 2024. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the $995,239 award aims to facilitate improved animal husbandry practices by providing natural supplements that can replace prophylactic antibiotics, drugs, and hormones in animal feed. The recipient will...
This Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of advanced enzymatic and computational strategies to enable the cost-effective synthesis of longer, more complex human milk oligosaccharides (HMOs) at scale. The $2,137,722 project, awarded to Novozymes, Inc., aims to engineer glycosyltransferases and transglucosidases to synthesize these essential nutrients found in human breast milk, which are currently difficult to produce in large quantities for infant formula. The project will leverage recent advances in cell-free protein synthesis, protein engineering, and machine learning to analyze enzyme structure-function relationships and design libraries for improved activity and selectivity. The goal is to ultimately demonstrate the feasibility of a lab-scale, cell-free process for producing commercially relevant HMOs, which will strengthen the U.S. bioeconomy through new, globally competitive bioproducts that support infant health and development.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.1m | 7/28/25 |